I-MAB-SPONSORED ADR (IMAB)

Company Profile

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Shanghai, Shanghai and currently employs 318 full-time employees. The company went IPO on 2020-01-17. The firm's main businesses include engaging in track record in innovation, developing innovative drug candidates and conduct clinical validation of the assets and commercialization. The firm's pipeline is composed of ten clinical-stage assets and ten preclinical assets, among which seven assets have moved to Phase 2 or Phase 3 clinical trial stage. Its pipeline is expected to yield three near-term NDA filings and/or product launches, including felzartamab for multiple myeloma (MM), eftansomatropin alfa for pediatric growth hormone deficiency (PGHD), and potentially lemzoparlimab for myelodysplastic syndromes (MDS) and later for acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL).

Company Info

I-MAB-SPONSORED ADR

55Th-56Th Floor, New Bund Center, 555 West Haiyang Road, Pudong District

Shanghai SHANGHAI 201210

P: 862160578000

CEO: Joan Huaqiong Shen

Employees: 318

Website: https://www.i-mabbiopharma.com/